Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Impetigo Treatment Misses Ph II Endpoint | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Impetigo Treatment Misses Ph II Endpoint

NovaBay, Galderma to assess development

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

NovaBay Pharmaceuticals completed its Phase IIb clinical study of auriclosene in the treatment of impetigo. While the study showed that auriclosene is safe and well tolerated, it did not meet its primary clinical endpoint. NovaBay and development partner Galderma are examining the results from this study and expect to use the findings to guide the future course of the clinical development for auriclosene. NovaBay expects to provide an update in the near future.

Under the terms of an exclusive licensing agreement, Galderma is responsible for the clinical development for auriclosene for impetigo. The agreement is global in scope and provides Galderma with an option for Galderma to license auriclosene for use in other dermatological indications

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics